Ergomed (LON:ERGO) said the first patient has been recruited into the Phase IIa study it is undertaking with Ferrer under the parties' co-development agreement.
The study is a Phase IIa clinical trial testing the efficacy, safety and tolerability profile of Lorediplon in adult patients with insomnia disorder, and is scheduled to be completed by the end of next year.
It follows a successful clinical trial of Lorediplon in 2012 that successfully demonstrated dose related clinical benefits in measured sleep parameters that were either as good as, or better than, prescription medication zolpidem in terms of the maintenance and quality of the sleep that the trial subjects achieved.
"Lorediplon has previously demonstrated promising results in pre-clinical and clinical studies, and we believe it has the potential to treat patients within insomnia and related sleep disorders, which remains an underserved market where new treatments are needed. The study is on track and we look forward to first data in 2016," said Miroslav Reljanovic, chief executive officer of Ergomed.